Dose-specific clinical outcomes in patients with opioid use disorder treated with 24-32 mg/day of buprenorphine.

Autor: D'Agata Mount J; The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA., Sun J; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA., Davis A; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA., Cover A; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA., Sun L; Haverford College, Haverford, PA, USA., Gannon C; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA., Derenoncourt M; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA., Garrett G; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA., Eyasu R; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA., Ebah E; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA., Bijole P; HIPS, Org, Washington, DC, USA., Greenblatt A; Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA., Kattakuzhy S; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA., Rosenthal E; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.

Publikováno v: Addiction (Abingdon, England) [Addiction] 2024 Nov; Vol. 119 (11), pp. 1964-1972. Date of Electronic Publication: 2024 Jul 08.

Hepatitis C cure and medications for opioid use disorder improve health-related quality of life in patients with opioid use disorder actively engaged in substance use.

Autor: Spaderna M; Department of Psychiatry, University of Maryland School of Medicine, 110 South Paca Street 4(th) Floor, Baltimore, Maryland 21201, United States. Electronic address: mspaderna@som.umaryland.edu., Kattakuzhy S; Department of Psychiatry, University of Maryland School of Medicine, 110 South Paca Street 4(th) Floor, Baltimore, Maryland 21201, United States; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, Maryland 21201, United States; DC Partnership for HIV/AIDS Progress, Clinical Research Program, Washington, District of Columbia, United States., Kang SJ; Genetic Epidemiology Research Branch, Intramural Research Program, National Institute of Mental Health, 35 Convent Drive, MSC 3720, Bldg 35A, Room 2E422A, Bethesda, Maryland 20892, United States., George N; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, Maryland 21201, United States., Bijole P; HIPS, 906 H Street NE, Washington, District of Columbia 20002, United States., Ebah E; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, Maryland 21201, United States; DC Partnership for HIV/AIDS Progress, Clinical Research Program, Washington, District of Columbia, United States., Eyasu R; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, Maryland 21201, United States; DC Partnership for HIV/AIDS Progress, Clinical Research Program, Washington, District of Columbia, United States., Ogbumbadiugha O; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, Maryland 21201, United States; DC Partnership for HIV/AIDS Progress, Clinical Research Program, Washington, District of Columbia, United States., Silk R; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, Maryland 21201, United States; DC Partnership for HIV/AIDS Progress, Clinical Research Program, Washington, District of Columbia, United States., Gannon C; DC Partnership for HIV/AIDS Progress, Clinical Research Program, Washington, District of Columbia, United States; Critical Care Medicine Department, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, United States., Davis A; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, Maryland 21201, United States; DC Partnership for HIV/AIDS Progress, Clinical Research Program, Washington, District of Columbia, United States., Cover A; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, Maryland 21201, United States; DC Partnership for HIV/AIDS Progress, Clinical Research Program, Washington, District of Columbia, United States., Gayle B; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, Maryland 21201, United States; DC Partnership for HIV/AIDS Progress, Clinical Research Program, Washington, District of Columbia, United States., Narayanan S; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, Maryland 21201, United States., Pao M; Office of the Clinical Director, National Institute of Mental Health, National Institutes of Health, 6001 Executive Boulevard, Room 6200, Bethesda, Maryland 20892, United States., Kottilil S; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, Maryland 21201, United States; DC Partnership for HIV/AIDS Progress, Clinical Research Program, Washington, District of Columbia, United States., Rosenthal E; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, Maryland 21201, United States; DC Partnership for HIV/AIDS Progress, Clinical Research Program, Washington, District of Columbia, United States.

Publikováno v: The International journal on drug policy [Int J Drug Policy] 2023 Jan; Vol. 111, pp. 103906. Date of Electronic Publication: 2022 Nov 13.

Suboptimal Uptake, Retention, and Adherence of Daily Oral Prexposure Prophylaxis Among People With Opioid Use Disorder Receiving Hepatitis C Virus Treatment.

Autor: Brokus C; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Kattakuzhy S; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Gayle B; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Narayanan S; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Davis A; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Cover A; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Eyasu R; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Ebah E; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Ogbumbadiugha-Weekes O; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Hoffmann J; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Silk R; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Stevens J; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA., Mount J; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA., Gannon C; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA., Nussdorf L; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA., Mathur P; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Bijole P; HIPS, Washington, District of Columbia, USA., Jones M; HIPS, Washington, District of Columbia, USA., Kier R; HIPS, Washington, District of Columbia, USA., Sternberg D; HIPS, Washington, District of Columbia, USA., Greenblatt A; Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA.; Department of Family and Community Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA., Weintraub E; Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA., Masur H; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA., Kottilil S; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Rosenthal E; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Publikováno v: Open forum infectious diseases [Open Forum Infect Dis] 2021 Dec 29; Vol. 9 (3), pp. ofab658. Date of Electronic Publication: 2021 Dec 29 (Print Publication: 2022).

Subspecialty physicians' perspectives on barriers and facilitators of hepatitis C treatment: a qualitative study.

Autor: Bredenberg, Erin¹ (AUTHOR) Erin.Bredenberg@CUAnschutz.edu, Callister, Catherine¹ (AUTHOR), Dafoe, Ashley² (AUTHOR), Holliman, Brooke Dorsey² (AUTHOR), Rowan, Sarah E.^3,4 (AUTHOR), Calcaterra, Susan L.^1,2,5 (AUTHOR)

Publikováno v: Harm Reduction Journal. 7/25/2024, Vol. 21 Issue 1, p1-9. 9p.

Hepatitis C treatment outcomes among people who inject drugs experiencing unstable versus stable housing: Systematic review and meta-analysis.

Autor: Kimball, Sarah¹ (AUTHOR) sk9260@nyu.edu, Reynoso, Marley¹ (AUTHOR), McKnight, Courtney^1,2 (AUTHOR), Des Jarlais, Don^1,2 (AUTHOR)

Publikováno v: PLoS ONE. 4/26/2024, Vol. 19 Issue 4, p1-16. 16p.